According to the phase II I-SPY2 trial (NCT01042379), the combination of cemiplimab and a lymphocyte activation gene-3 (LAG-3) inhibitor, fianlimab along with paclitaxel exhibited a significant pathologic complete response than paclitaxel alone in HR + and HER2 − breast cancer or TNBC patients [163]. The gene discussed is LAG3; the disease is breast carcinoma.